Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 7 studies | 48% ± 20% | |
GABAergic neuron | 5 studies | 37% ± 11% | |
interneuron | 3 studies | 49% ± 14% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 46% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 85% | 138.95 | 2246 / 2642 | 21% | 0.70 | 149 / 705 |
ovary | 82% | 133.82 | 147 / 180 | 9% | 0.25 | 37 / 430 |
stomach | 72% | 85.75 | 259 / 359 | 1% | 0.03 | 4 / 286 |
thymus | 42% | 16.64 | 272 / 653 | 7% | 0.19 | 40 / 605 |
uterus | 43% | 71.65 | 73 / 170 | 4% | 0.23 | 18 / 459 |
adrenal gland | 1% | 0.21 | 2 / 258 | 43% | 2.03 | 100 / 230 |
esophagus | 35% | 19.03 | 499 / 1445 | 1% | 0.02 | 1 / 183 |
prostate | 16% | 9.39 | 38 / 245 | 1% | 0.02 | 3 / 502 |
pancreas | 8% | 2.82 | 25 / 328 | 1% | 0.03 | 2 / 178 |
breast | 0% | 0 | 0 / 459 | 6% | 0.23 | 70 / 1118 |
skin | 4% | 1.49 | 67 / 1809 | 0% | 0.03 | 2 / 472 |
lung | 0% | 0.04 | 1 / 578 | 4% | 0.13 | 41 / 1155 |
kidney | 2% | 0.58 | 2 / 89 | 1% | 0.01 | 6 / 901 |
intestine | 2% | 0.67 | 22 / 966 | 1% | 0.02 | 3 / 527 |
bladder | 0% | 0 | 0 / 21 | 3% | 0.17 | 13 / 504 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.03 | 1 / 45 |
eye | 0% | 0 | 0 / 0 | 1% | 0.02 | 1 / 80 |
liver | 0% | 0.17 | 1 / 226 | 0% | 0.01 | 2 / 406 |
adipose | 0% | 0.04 | 1 / 1204 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 0 | 0 / 1335 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007198 | Biological process | adenylate cyclase-inhibiting serotonin receptor signaling pathway |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
GO_0007268 | Biological process | chemical synaptic transmission |
GO_0007187 | Biological process | G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger |
GO_0030425 | Cellular component | dendrite |
GO_0045202 | Cellular component | synapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0051378 | Molecular function | serotonin binding |
GO_0004930 | Molecular function | G protein-coupled receptor activity |
GO_0004993 | Molecular function | G protein-coupled serotonin receptor activity |
GO_0030594 | Molecular function | neurotransmitter receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | HTR1E |
Protein name | 5-hydroxytryptamine receptor 1E (5-HT-1E) (5-HT1E) (S31) (Serotonin receptor 1E) |
Synonyms | |
Description | FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. . |
Accessions | P28566 ENST00000305344.7 |